Post-Prandial Liver Glucose Metabolism in PCOS: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Post-Prandial Liver Glucose Metabolism in PCOS (NCT03041129), a registered phase not stated study. The primary outcome is Hepatic Fat Fraction.

2. Clinical Question

The scientific question concerns liver metabolism in the context of PCOS, obesity, and hepatic steatosis. These concepts describe the motivation and comparison groups, not a finding: the registry record does not report whether hepatic metabolism was upregulated, or whether hepatic fat fraction differed among groups. It also does not report a specific primary statistical contrast or an inferential result for the comparison.

3. Trial Design

The record identifies NCT03041129, titled “Post-Prandial Liver Glucose Metabolism in PCOS,” as a completed study sponsored by the University of Colorado, Denver. The listed enrollment is 19. The study began on 2017-04-14, and the primary completion date is 2018-08-29. Those registry entries describe the study’s status and timeline, but do not establish how many participants contributed data to the primary endpoint.

The intervention entries are an oral glucose tolerance test and an MRI of the liver, both classified as diagnostic tests. The primary measure is hepatic fat fraction. The record describes PCOS groups that are untreated apart from lifestyle treatment, taking metformin, or taking an oral contraceptive, and an obese control group. The medication groups and the obese control group are explicitly marked “Study arm not funded.” The PCOS arm descriptions specify PCOS per NIH criteria; the medication descriptions also specify minimum doses and duration. The control description specifies regular menses and time since menarche.

The registry record does not state the allocation method. It explicitly cautions that this is not a randomized comparison and that the arms are not a like-for-like control comparison. Thus, the group descriptions alone do not establish that participants were assigned to groups in a way that supports causal treatment comparisons. Whether any group comparison was planned or conducted in a particular adjusted or unadjusted form is not reported in the registry record.

The record lists secondary outcomes related to hepatic metabolism ratios, whole-body insulin sensitivity, sleep duration, sleep quality, and hepatic phosphate concentrations. It does not report the detailed measurement schedule or statistical analysis plan for these outcomes. The endpoint timeframe is described as measured up to 4 months from enrollment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Adolescent females with dx of PCOS

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Only participants enrolled in the untreated PCOS group. No participants were enrolled in the other arms of the study due to funding.

6. Primary Endpoint

The registry lists the primary outcome as Hepatic Fat Fraction, measured over Measured up to 4 months from enrollment.

The primary endpoint is hepatic fat fraction, reported as a mean of a continuous measure with standard deviation as its dispersion measure. It is expressed as a percent and measured using MRI. The description says the value is calculated by the Dixon method as proton density hepatic fat fraction, which ranges from 0-75%. The registry states that a value greater than 5% is considered extra fat in the liver.

This measure is used to quantify liver fat rather than to record a clinical event. A continuous measure can preserve variation across participants, while a threshold can provide a categorical interpretation of whether the value is considered extra fat under the registry’s definition. Those are distinct ways to interpret the measure: the mean describes the group’s average, while a threshold classifies values relative to a stated criterion.

For this study, the endpoint is relevant to the stated question about hepatic metabolism and hepatic steatosis among adolescent females with PCOS. However, the registry record does not report the mean hepatic fat fraction, its standard deviation, the number contributing data, or a comparison estimate. Consequently, the endpoint definition can be described, but the observed amount of liver fat and the precision of any group comparison cannot be evaluated from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary endpoint is a continuous measurement summarized using a mean and standard deviation. The mean describes the central value across the observations included in a group. The standard deviation describes how spread out individual measurements are around that mean. It is not, by itself, a measure of the precision of the mean or of a difference between groups. A confidence interval is a general statistical tool for expressing uncertainty around an estimate; no confidence interval for hepatic fat fraction is reported in the registry record.

What does a continuous endpoint capture?

As a general statistical point, retaining a measurement on its continuous scale can distinguish degrees of a characteristic that would be collapsed by a simple yes-or-no classification. In this record, hepatic fat fraction is expressed as a percent, and the description gives a measurement range of 0-75%. The registry also identifies greater than 5% as extra fat in the liver. That threshold may aid clinical or descriptive classification, but a threshold-based classification and a comparison of group means answer different questions. The registry record does not report either group-level continuous results or the number of participants above the threshold.

Means and standard deviations are most straightforward to interpret when the distribution is reasonably represented by its mean and spread. As a general point, a mean can be influenced by unusually high or low observations, especially in a small dataset. A standard deviation helps describe dispersion but does not reveal the full distribution, skewness, or the presence of outliers. No distributions, individual observations, or additional summaries are reported for this endpoint, so these features cannot be assessed.

What would a group comparison require?

A comparison needs a defined estimand: for example, a specified difference in mean hepatic fat fraction between clearly identified groups. The registry states the broad research question and group descriptions, but does not report the exact primary contrast or the statistical test used. It also does not report an adjusted model, covariates, or an estimate of between-group difference. The allocation method is not stated, and the record warns that the groups are not a like-for-like control comparison. General statistical interpretation therefore distinguishes an observed association between group membership and an outcome from a causal effect of treatment; the record does not support attributing any difference to a medication or other intervention.

Uncertainty should be considered alongside an estimate. In general, a confidence interval communicates a range of values compatible with the data under the model used, and its width reflects precision. A p-value, when reported, addresses compatibility with a specified null hypothesis under statistical assumptions; it does not measure clinical importance. Neither a p-value nor a confidence interval for the primary endpoint is reported in the registry record. There is therefore no basis to describe statistical significance, precision, or the magnitude of a group difference.

What can be inferred from the design description?

The record lists oral glucose tolerance testing and liver MRI as diagnostic tests. It does not describe a randomized allocation process. The arm labels and medication-use criteria identify participant groups, but do not show that the groups were assigned to interventions. General statistical reasoning treats nonrandomized group comparisons cautiously because participants may differ in ways related to both group membership and the endpoint. The registry’s own warning that the arms are not a like-for-like control comparison reinforces the need for caution, while the record does not state whether or how potential differences were addressed analytically.

The sample-size assumptions describe planning illustrations based on the observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect described as a fraction of the observed effect. Such illustrations are planning calculations, not observed power. The record does not report numerical sample-size illustrations or a protocol-based sample-size justification. It also does not report the observed endpoint effect needed to evaluate the basis of those illustrations. No inference about the trial’s original design rationale or achieved ability to detect an effect can be made from those assumptions alone.

Finally, the registry identifies six outcome measures and no analyses in the posted results. General methods for handling multiple outcomes may include a prespecified hierarchy or adjustment of inferential thresholds, but the registry record does not report a multiplicity plan. Nor does it report missing-data methods, analysis populations, model diagnostics, or a statistical analysis plan. These absences limit reproducibility and make it impossible to determine whether any particular analysis was prespecified or how its assumptions were checked.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Untreated PCOS")
n   <- c(17)
m   <- c(8.35)
sp  <- c(7.55)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Untreated PCOS  17  8.350  7.550  4.468  12.232

11. Multiplicity, Missing Data and Analysis Populations

The registry lists six outcome measures: the primary hepatic fat fraction endpoint and secondary outcomes concerning hepatic metabolism ratios, whole-body insulin sensitivity, sleep duration, sleep quality, and hepatic phosphate concentrations. The record reports no analyses. It does not state whether outcomes were tested in a hierarchy, whether one endpoint was designated as the sole basis for formal inference, or whether any adjustment for multiple comparisons was planned. These multiplicity details are not reported in the registry record.

Multiplicity matters in general because evaluating several outcomes or contrasts can increase the chance of obtaining at least one apparently notable result by chance. A prespecified analysis hierarchy or a suitable adjustment can help readers interpret a family of tests, but no such approach can be attributed to this study based on the registry record. With no posted estimates or test results, there is also no basis to assess how multiplicity affected any reported conclusion.

The number of participants enrolled is 19, but the registry does not state the number with endpoint data, the number included in any analysis, or the handling of incomplete measurements. Missing-data rates, reasons for missingness, imputation, and sensitivity analyses are not reported in the registry record. The record also does not identify an intention-to-treat, per-protocol, or other analysis population for the primary endpoint.

These omissions do not establish that data were missing or that a particular method was used. They mean that the extent and treatment of missingness, the analysis set, and the control of multiplicity cannot be verified from the posted record. Those details would be important for judging how robust any eventual comparisons are.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

For the untreated PCOS group, the registry reports 17 participants at risk for serious adverse events and 0 affected. It also reports 17 at risk for other adverse events and 0 affected, with 0 deaths. These figures describe the safety entries recorded for that group; they do not provide event details beyond the counts.

The metformin PCOS, oral contraceptive PCOS, and obese control groups each show 0 participants at risk in the adverse-event fields, with 0 affected and 0 deaths. A zero denominator does not provide an evaluable safety experience for those groups. In particular, the zeros in those rows should not be read as evidence that no events occurred among participants who received those treatments or belonged to those groups.

The registry record does not report the safety observation period, event definitions beyond the serious and other adverse-event categories, or additional details about ascertainment. It lists no top serious adverse-event terms. The reported counts therefore need to be read narrowly, as registry entries for the stated risk sets, rather than as a complete account of safety or a comparison of event rates between groups.

13. What the Result Does, and Does Not, Mean

The registry record establishes that the study was completed, enrolled 19 participants, and designated MRI-measured hepatic fat fraction as its primary endpoint for adolescent females with PCOS. It also describes diagnostic procedures, participant groups, secondary outcomes, and a timeframe of measurement up to 4 months from enrollment. These are useful details about the research question and the intended measurements.

However, the posted results do not report the mean hepatic fat fraction or its standard deviation, nor any group comparison, confidence interval, or statistical test. Accordingly, the record does not show whether the groups differed, how large any difference might have been, or how precisely a difference was estimated. It also does not report how many participants contributed primary endpoint data. The stated definition that greater than 5% is considered extra fat is not a reported result about participants.

The record does not establish that metformin, oral contraceptives, or lifestyle treatment caused any difference in liver fat or hepatic metabolism. Allocation is not stated, the registry cautions that the arms are not a like-for-like control comparison, and the medication groups are marked as not funded. The group labels should not be interpreted as evidence of random assignment or as proof of a causal contrast.

In general, absence of a reported result is not evidence that groups were identical, and it is not evidence that a difference existed. It means the result cannot be evaluated from the registry record. The most defensible conclusion is descriptive: the registry lays out a question about hepatic metabolism and PCOS-related groups, but the empirical findings needed to answer that question are not reported.

14. Why This Trial Matters Statistically

This record is statistically informative in showing why a clearly specified endpoint is only one part of an interpretable trial record. Hepatic fat fraction is defined as a continuous MRI-derived measure, with a stated calculation method, range, and threshold for extra liver fat. That information helps clarify what researchers intended to measure. It does not, without observed values and uncertainty estimates, show what was found.

The study also illustrates the importance of distinguishing enrollment from analysis. The registry lists enrollment of 19, while the number with primary endpoint measurements and the analysis population are not reported. Without those details, a reader cannot determine the effective information available for estimating group means or differences. General statistical reasoning emphasizes that estimates from limited data may be imprecise, but the precision in this study cannot be quantified from the registry record.

Its comparison structure also matters. The groups have different descriptions, the allocation method is not stated, and the registry cautions that this is not a like-for-like control comparison. These features make it important to distinguish descriptive comparisons from causal conclusions. The record does not report an adjustment strategy or a statistical plan that would clarify how group differences were to be interpreted.

Finally, the listing of multiple outcomes makes transparent reporting of analysis choices particularly valuable. The registry does not describe multiplicity handling, missing-data methods, or endpoint analyses. These are not merely technical details: they affect how readers assess uncertainty, reproducibility, and the strength of conclusions. In this case, their absence, together with the absence of endpoint results, limits statistical interpretation to the design and measurement information that is actually recorded.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation for interpretation is the absence of posted endpoint results. The registry does not report hepatic fat fraction values, variability, group contrasts, or inferential statistics. It also does not report participant counts for the endpoint analysis. As a result, neither the magnitude nor precision of the primary outcome can be evaluated.

The total enrollment is 19, but the registry record does not clarify how participants were distributed across groups or whether all described groups contributed data. The metformin and oral contraceptive PCOS groups and the obese control group are marked as not funded; their adverse-event risk sets are recorded as zero. The record does not explain how that funding status relates to enrollment or to the primary outcome data. No assumptions about their participation or results can be made from the labels alone.

The allocation method is not stated, and the record explicitly says this is not a randomized comparison and that the arms are not a like-for-like control comparison. The descriptions include different clinical and treatment characteristics, which makes unadjusted comparisons difficult to interpret as effects of a treatment. The record does not report covariate adjustment, matching, or another strategy for addressing group differences.

Other important details are not reported in the registry record: the primary statistical contrast, analysis population, missing-data approach, multiplicity plan, protocol-based sample-size justification, and analysis diagnostics. The endpoint timeframe is given as up to 4 months from enrollment, but the timing and completeness of measurements are not described. These limitations constrain what can be concluded from the record; they do not establish that the study used any particular unreported method or that any particular bias occurred.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Post-Prandial Liver Glucose Metabolism in PCOS — NCT03041129.
• Registry record last updated 2024-04-17; status last verified 2024-04.
• Results first posted 2024-04-17.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03041129, “Post-Prandial Liver Glucose Metabolism in PCOS,” is listed as completed, sponsored by the University of Colorado, Denver, and enrolling 19 participants. Its primary endpoint is MRI-derived hepatic fat fraction, described as a continuous measure summarized by its mean and standard deviation, in adolescent females with PCOS. Measurement was specified for up to 4 months from enrollment.

The record lists an oral glucose tolerance test and liver MRI, and describes untreated PCOS, medication-treated PCOS, and obese control groups. It cautions that the comparison is not randomized and that the arms are not a like-for-like control comparison. The posted results report no analyses or primary endpoint values. Thus, the registry record documents the question and measurement approach but does not report findings that answer the question.